Financial Reports
Our financial reports are only available in Swedish.
AcuCort publishes the Interim Report for the first quarter 2022 (in Swedish)
Message from the CEO
“The year began at a high pace and during the second quarter we have maintained a high level of activity to get all the important parts in place for the successful commercialization of ISICORT®.”
Jonas Jönmark, CEO, AcuCort AB
August 12, 2022
We make good drugs better
AcuCort develops innovative treatments based on existing and well-documented substances in treatment areas where there is a high unmet medical need and commercial interest in new drugs that add benefits such as simplicity of administration.